PhenomeX Strengthens Commercial Leadership Team
PhenomeX (Nasdaq: CELL) has appointed Dr. Yan Zhang as Chief Commercial Officer, effective immediately, to enhance its global commercial strategy. Dr. Zhang, with nearly 25 years in the life sciences industry and experience from Mission Bio and Thermo Fisher Scientific, will lead the expanded commercial organization following the merger of Berkeley Lights and IsoPlexis. Additionally, Tomoya Aoyama will manage commercial operations in the APAC region. Both leaders are expected to drive strategic growth and strengthen the company's market presence in a key growth area. This leadership change aligns with PhenomeX’s goal of advancing cell biology and therapeutics.
- Appointment of Dr. Yan Zhang is expected to strengthen leadership and drive strategic growth.
- Enhanced leadership team with experienced professionals in life sciences, key for growth in critical global markets.
- None.
Appoints Dr.
In the newly created CCO role,
"We are incredibly excited to welcome
"It is a privilege to serve as CCO for PhenomeX at the start of the Company's story," said
"I am thrilled to welcome Aoyama-san to the growing regional commercial teams at PhenomeX," concluded
About
PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding PhenomeX or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. PhenomeX undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/phenomex-strengthens-commercial-leadership-team-301777203.html
SOURCE PhenomeX
FAQ
Who is the new Chief Commercial Officer of PhenomeX?
What will Dr. Zhang's role entail at PhenomeX?
Who is overseeing commercial operations in the APAC region for PhenomeX?
What experience does Dr. Zhang bring to PhenomeX?